Research status of different doses of anti-vascular endothelial growth factor drugs in retinopathy of prematurity

With the further study of vascular endothelial growth factor (VEGF) in the pathogenesis of retinopathy of prematurity (ROP), a variety of anti-VEGF drugs with 1/2 adult dose have been used at home and abroad to treat ROP, and initially achieved remarkable curative effect.However, further studies have shown that anti-VEGF drugs can enter the systemic circulation through the vitreous cavity, which temporarily reduces serum VEGF levels in children.As a result, it may have potential systemic side effects for premature infants during the period of rapid growth and development.At present, experts at home and abroad have begun to pay attention to the risk of systemic side effects of ROP treated with 1/2 adult dose, and have conducted a variety of low-dose anti-VEGF drugs in the treatment of ROP.However, most of the studies are retrospective studies with small samples, and there is a lack of multicenter prospective studies with large samples.Therefore, all doses of anti-VEGF drugs in the treatment of ROP need to be further investigated.This article reviews the efficacy and problems of different doses of anti-VEGF drugs in the treatment of ROP to provide a reference for the treatment of ROP.

Retinopathy of prematurity; Vascular endothelial growth factor; Angiogenesis inhibitors; Dose; Treatment outcome